These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 17804114)

  • 21. CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation.
    Pan M; Santamaria M; Wollman DB
    Nat Clin Pract Oncol; 2007 Oct; 4(10):603-7. PubMed ID: 17898810
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cutaneous side-effects of epidermal growth factor receptor-tyrosine kinase inhibitor (TKI) in the treatment of lung cancer: description and its management.
    Ong CK; Tan WC; Chan LC; Abdul Razak M
    Med J Malaysia; 2012 Apr; 67(2):222-3. PubMed ID: 22822651
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib.
    Omuro AM; Kris MG; Miller VA; Franceschi E; Shah N; Milton DT; Abrey LE
    Cancer; 2005 Jun; 103(11):2344-8. PubMed ID: 15844174
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fatal interstitial lung disease after erlotinib administration in a patient with radiation fibrosis.
    Um SJ; Lee SK; Yang DK; Son C; Roh MS; Kim KN; Lee KN; Choi PJ
    Clin Respir J; 2009 Jul; 3(3):181-4. PubMed ID: 20298401
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Erlotinib response of EGFR-mutant gefitinib-resistant non-small-cell lung cancer.
    Chang JW; Chou CL; Huang SF; Wang HM; Hsieh JJ; Hsu T; Cheung YC
    Lung Cancer; 2007 Dec; 58(3):414-7. PubMed ID: 17618013
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Successful treatment with erlotinib after gefitinib-induced interstitial lung disease: a case report and literature review.
    Koma Y; Matsuoka H; Yoshimatsu H; Suzuki Y
    Int J Clin Pharmacol Ther; 2012 Oct; 50(10):760-4. PubMed ID: 22853866
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recurrent responses to non-small cell lung cancer brain metastases with erlotinib.
    Popat S; Hughes S; Papadopoulos P; Wilkins A; Moore S; Priest K; Meehan L; Norton A; O'Brien M
    Lung Cancer; 2007 Apr; 56(1):135-7. PubMed ID: 17157952
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [A case of lung cancer with skin metastases responding to erlotinib].
    Sasaki Y; Minamiya Y; Okuyama M; Hibino M; Kudo S; Tenma K; Nakamura M; Ogawa J
    Gan To Kagaku Ryoho; 2011 Feb; 38(2):271-4. PubMed ID: 21368493
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [A case of adenocarcinoma of lung cancer with multiple brain metastasis and lymphangitis carcinomatosa responding well to chemotherapy with carboplatin, etoposide and ifosfamide].
    Hojo K; Kumasaka Y; Nishiyama S; Higashihara T; Oku Y; Okada M; Kajiyama K
    Gan To Kagaku Ryoho; 1992 Dec; 19(14):2403-6. PubMed ID: 1463347
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up.
    Ruppert AM; Beau-Faller M; Neuville A; Guerin E; Voegeli AC; Mennecier B; Legrain M; Molard A; Jeung MY; Gaub MP; Oudet P; Quoix E
    Eur Respir J; 2009 Feb; 33(2):436-40. PubMed ID: 19181917
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term survival following concurrent chemoradiotherapy in patients with non-small-cell lung cancer with concomitant brain metastases only.
    Harita S; Mizuta A; Kuyama S; Kikuchi T
    Int J Clin Oncol; 2005 Feb; 10(1):63-8. PubMed ID: 15729604
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI.
    Yi HG; Kim HJ; Kim YJ; Han SW; Oh DY; Lee SH; Kim DW; Im SA; Kim TY; Kim CS; Heo DS; Bang YJ
    Lung Cancer; 2009 Jul; 65(1):80-4. PubMed ID: 19059670
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasma MIP-1beta levels and skin toxicity in Japanese non-small cell lung cancer patients treated with the EGFR-targeted tyrosine kinase inhibitor, gefitinib.
    Kimura H; Kasahara K; Sekijima M; Tamura T; Nishio K
    Lung Cancer; 2005 Dec; 50(3):393-9. PubMed ID: 16153743
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epidermal growth factor receptor targeted therapy with gefitinib in locally advanced and metastatic primary lung adenocarcinoma.
    Liam CK; Pang YK; Leow CH
    Respirology; 2006 May; 11(3):287-91. PubMed ID: 16635086
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer.
    Kobayashi T; Koizumi T; Agatsuma T; Yasuo M; Tsushima K; Kubo K; Eda S; Kuraishi H; Koyama S; Hachiya T; Ohura N
    Cancer Chemother Pharmacol; 2012 May; 69(5):1241-6. PubMed ID: 22278730
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pulsed reduced dose-rate radiotherapy as re-irradiation for brain metastasis in a patient with lung squamous-celled carcinoma.
    Li GH; Liu Y; Tang JL; Zhang D; Zhou P; Yang DQ; Ma CK
    Jpn J Clin Oncol; 2012 Sep; 42(9):856-60. PubMed ID: 22701036
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: a case report and review of the literature.
    Togashi Y; Masago K; Hamatani Y; Sakamori Y; Nagai H; Kim YH; Mishima M
    Lung Cancer; 2012 Aug; 77(2):464-8. PubMed ID: 22579408
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bilateral subdural hematoma associated with central nervous system metastases from lung cancer.
    Hata A; Fujita S; Katakami N; Sakai C; Imai Y
    J Thorac Oncol; 2011 Jan; 6(1):207-8. PubMed ID: 21178717
    [No Abstract]   [Full Text] [Related]  

  • 40. Erlotinib-Associated Rash Exacerbated by Whole-Brain Radiation Therapy: A Patient's Case Report.
    Erikson AK; Yu NY; Sheedy JT; Shoudis SN; Paripati HR; Sio TT
    Pract Radiat Oncol; 2019 May; 9(3):128-131. PubMed ID: 30770236
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.